BioNTech’s Phase 3 Win: Why Patient Benefit May Still Be Limited

On October 26, 2026, BioNTech and DualityBio announced a result that initially sounded like a milestone worth celebrating. Their HER2-directed antibody-drug conjugate BNT323, also known as DB-1303 or trastuzumab pamirtecan, met the primary endpoint of the global Phase 3 DYNASTY-Breast02 trial.

The same announcement, however, said that the available efficacy and safety data suggested limited potential patient benefit in the treatment setting studied. [1]

Both statements can be true. A trial answers a prespecified question. A product decision also requires judging whether the answer is compelling enough to change treatment choices.

What does statistical success establish?

DYNASTY-Breast02 enrolled 541 patients with hormone receptor-positive, HER2-low metastatic breast cancer who had progressed on endocrine therapy and had not received chemotherapy for metastatic disease. It compared BNT323 with the investigator’s choice of single-agent chemotherapy.

The companies reported a statistically significant but modest improvement in progression-free survival, or PFS. Overall survival data were immature. [1]

A statistical test assesses how incompatible the observed difference is with a hypothesis of no treatment difference, under the test’s assumptions. It does not, by itself, establish whether the additional disease control is large enough to change a patient’s treatment decision.

Investors therefore need to ask how long the improvement lasts, which patients benefit most and what treatment burden accompanies that benefit. Meeting the prespecified statistical threshold is the beginning of that assessment. The product’s eventual position depends on the answers that follow.

Existing treatments raise the competitive bar

The control arm was chemotherapy. This treatment landscape already includes another HER2-directed ADC: Enhertu, or fam-trastuzumab deruxtecan-nxki.

In January 2025, the FDA approved Enhertu for certain patients with unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer that had progressed on one or more endocrine therapies in the metastatic setting. [2]

A later entrant must therefore be assessed both against its trial comparator and within the treatment pathway clinicians face today. Treatment selection also depends on available alternatives, prior therapy, toxicity management and the options that remain afterward.

DYNASTY-Breast02 did not directly compare BNT323 with Enhertu. Separate trials cannot establish a reliable ranking between the two drugs. Nevertheless, the presence of an established option raises a practical question: for which patients could the new product offer sufficiently clear additional value?

Safety matters in relation to the size of the benefit

The companies also reported more interstitial lung disease than in previous trastuzumab pamirtecan trials. Most cases were Grade 1 or 2, but severe or fatal Grade 3–5 events occurred in a small proportion of patients. [1]

The significance of that risk depends on the benefit available in return. The same toxicity can lead to different benefit–risk judgments at different disease stages and when different alternatives are available. If the additional disease control is modest, patients and clinicians may be more sensitive to the risks needed to obtain it.

The announcement did not provide the treatment groups’ median PFS values, the PFS hazard ratio or a complete breakdown of lung-event rates by grade. That leaves insufficient information for a precise quantitative benefit–risk comparison. Filling those gaps with assumed figures would create an appearance of precision that the disclosure does not support. [1]

What the announcement does establish is that the companies themselves are reconsidering how much patient value this statistically positive result can support.

Which part of BioNTech’s investment case needs updating?

BNT323 entered BioNTech’s pipeline through its partnership with DualityBio. The original 2023 agreements covered two assets, DB-1303 and DB-1311, with combined upfront payments of $170 million. BioNTech obtained commercial rights outside mainland China, Hong Kong and Macau. The upfront amount covered both assets; it should not be assigned entirely to BNT323. [3]

The collaboration created opportunities for future products. As evidence emerges, the value of those opportunities needs to be updated.

For investment analysis, regulatory approval, adoption after approval and the cost of further development deserve separate assumptions. A product expected to achieve limited use can warrant lower sales and return expectations even after a positive pivotal trial. Conversely, subsequent data identifying a population with a clearer benefit could help refine its positioning.

Past licensing and development expenditure shows how much has already been committed. The case for additional spending depends on the returns still available from today onward.

That assessment should remain specific to BNT323 and the indication studied. Other programs in BioNTech’s oncology pipeline require evaluation on their own evidence.

The most useful next information will be the complete efficacy and safety results, the companies’ development decision and the treatment position they intend to pursue. The companies have said they will discuss the data and determine next steps. [1]

Meeting a trial endpoint establishes the result of a clinical comparison. Product value faces a further test: is the improvement compelling enough for patients, clinicians and payers to choose it?

Sources and scope

Evidence cut-off: October 27, 2026. The investment and capital-allocation discussion is editorial analysis based on the sources below.

1. BioNTech and DualityBio: DYNASTY-Breast02 topline results, October 26, 2026. Primary source for this trial’s disclosed findings. Undisclosed efficacy and safety figures have not been estimated.
2. FDA: Enhertu approval in HR-positive, HER2-low or HER2-ultralow breast cancer, January 27, 2025. Provides the established-treatment context; no cross-trial efficacy ranking is made.
3. BioNTech and DualityBio: original ADC collaboration, April 3, 2023. Source for the original rights and combined upfront-payment terms.